Corporate News – Shenyang Xingqi Pharmaceutical
Shenyang Xingqi Pharmaceutical Co., Ltd. (ticker 300573.SZ) closed the trading day unchanged at 0 % on Friday, 23 November, with a closing price of CNY 34.83. The stock’s 24‑hour trading volume amounted to CNY 105.8 million, against a current supply of 88.6 million shares and a market capitalisation of CNY 3 billion. Since the end of last month, the share price has slipped ‑6.76 %.
Pricing Strategy Update
In a strategic move to strengthen its market foothold, Shenyang Xingqi announced a significant price reduction for its 0.01 % atropine sulfate eye drops—the sole domestically approved low‑concentration formulation for slowing myopia progression. The unit price has been cut by more than one‑fifth, falling from CNY 298 to CNY 234.70 per box. The decision reflects industry trends toward wider availability of low‑dose atropine therapies and is intended to improve patient access while preserving the company’s competitive advantage in a landscape increasingly crowded with alternative products.
The company reiterated its commitment to expanding channel coverage, enhancing clinical prescription uptake, and advancing its pipeline of eye‑care products, including investigational treatments for age‑related macular degeneration and diabetic retinopathy. The pricing adjustment is positioned as a balancing act between affordability and sustained revenue growth, reinforcing Shenyang Xingqi’s reputation for proactive market positioning.
Technical Snapshot
- Simple Moving Average (200‑day): CNY 38.68
- 52‑Week High: CNY 59.07 (30 Oct 2025)
- 52‑Week Low: CNY 32.70 (15 Oct 2026)
The current price sits below the 200‑day average, suggesting a short‑term downtrend, yet the recent price cut may serve as a catalyst for renewed investor interest.
Peer Performance (24 Hours)
| Stock | Ticker | Change | Current Price | Market Cap (CNY) | P/E Ratio |
|---|---|---|---|---|---|
| Anhui Expressway -H | 0995.HK | –1.04 % | HKD 16.1 | HKD 4.3 bn | 12.47 |
| Cheersson | 002976.SZ | 0 % | CNY 17.63 | CNY 3.6 bn | – |
| Hangzhou Flariant | 605566.SS | 0 % | CNY 26.00 | CNY 3.6 bn | 82.14 |
| Fulin Transportation | 002357.SZ | 0 % | CNY 11.21 | CNY 3.6 bn | 9.44 |
| Aoto Electronics | 002587.SZ | 0 % | CNY 5.89 | CNY 3.6 bn | 192.26 |
While most peers traded flat, the broader transportation sector saw a modest increase in financing balances, signalling a slight uptick in leveraged activity even as the Shanghai Composite Index experienced a dip on 22 October.
Forward‑Looking Outlook
Shenyang Xingqi’s recent pricing strategy is expected to:
- Stimulate Demand: Lowering the cost of a niche product is likely to broaden patient access and boost prescription volumes.
- Maintain Market Share: By pricing competitively, the company can defend its leadership position against emerging entrants in the low‑dose atropine space.
- Fuel Pipeline Development: Reinvesting proceeds into research for macular degeneration and diabetic retinopathy therapies will diversify revenue streams and mitigate reliance on a single product line.
Analysts anticipate that the price cut will generate a short‑term rally, provided that the company continues to execute its channel expansion and product development plans. Investors should monitor the company’s sales data and any forthcoming regulatory approvals that could further accelerate growth.
This article is intended for informational purposes only and does not constitute investment advice.